The specificity of the CD58 antibody employed in these analyses is confirmed by the data presented in Figure 6, which demonstrates specific binding in healthy controls, ALL, and CLL cases compared to unstained controls. The gene discussed is CD58; the disease is acute lymphoblastic leukemia.